India Pharma Outlook Team | Friday, 21 August 2026
Calcium Gluconate has become the latest addition to Glenmark Pharmaceuticals’ U.S. injectable portfolio.
The company recently launched calcium gluconate injection USP across three presentations in the American market.
The launch targets a market that recorded approximately 69.9 million in annual sales for these presentations in the 12 months ended June 2026, according to IQVIA data.
The opportunity adds commercial relevance to Glenmark’s continued focus on building its U.S. injectable portfolio and serving institutional healthcare demand. Glenmark also notes this move as its strategy to build a differentiated, sustainable U.S. injectables business focused on institutional demand and supply resilience.
Glenmark has launched calcium gluconate Injection USP in three dosage presentations. The product comes as a 1,000 mg/10 mL single-dose vial, a 5,000 mg/50 mL single-dose vial, and a 10,000 mg/100 mL pharmacy bulk package. Each presentation carries a concentration of 100 mg/mL.
The company’s calcium gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug manufactured by Fresenius Kabi USA, LLC. The U.S. launch therefore gives Glenmark access to multiple dosage formats within the same injectable market. The pharmacy bulk package also provides a distinct presentation for institutional and hospital-use settings.
According to the U.S. prescribing information for calcium gluconate injection, the product is indicated for pediatric and adult patients with acute symptomatic hypocalcemia. The approved indication and labeling remain specific to the product’s authorized label.
Also Read: Building Resilient QMS in Global Pharma Manufacturing
The calcium gluconate market represented by the three launched presentations generated approximately 69.9 million in annual U.S. sales during the 12 months ended June 2026, according to IQVIA data cited by Glenmark. The figure includes the brand and available therapeutic equivalents.
The market size gives context to Glenmark’s latest U.S. injectable launch. Rather than entering an untested product segment, the company has added a generic injectable to an established market with measurable commercial demand.
Glenmark also specifies that the product will carry only the indications included in its approved label. Those indications may differ from those authorized for the reference listed drug.
The calcium gluconate launch follows several U.S. injectable introductions by Glenmark during 2026. The company earlier launched Methylene Blue, Lacosamide, Olanzapine, and Sugammadex. Its 2026 U.S. pipeline also includes Sodium Phosphates Injection.
Marc Kikuchi, President and Business Head, North America, said the Calcium Gluconate Injection launch marks another step in strengthening Glenmark’s U.S. injectables business and expanding its hospital portfolio. The company links its strategy to institutional needs, supply resilience and a broader presence across the U.S. healthcare system.
The latest calcium gluconate launch therefore adds another product to Glenmark’s growing U.S. injectable offering while giving the company exposure to a market with approximately 69.9 million in annual sales.
